Nicole Nardella

Ms. Nicole Nardella

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JYJames Yu
James Yu
JLJose Laborde
Jose Laborde
RPRobin Park
Robin Park
MSMoazzam Shahzad
Moazzam Shahzad
Youngchul KimYoungchul Kim
Youngchul Kim
DKDae Won Kim
Dae Won Kim
Background: In patients with curatively resected pancreatic adenocarcinoma who have undergone neoadjuvant chemotherapy (NACT), evidence supporting the benefit of additional adjuvant chemotherapy (ACT) remains limited. We aim to identify favorable factors contributing to survival benefits in resected pancreatic adenocarcinoma after NACT. Methods: This is a retrospective cohort study of pancreatic adenocarcinoma patients who underwent NACT followed by curative surgical resection between 2008 and 2023 at a single academic institution. Univariate and multivariable analyses were conducted to identify factors contributing to disease-free survival (DFS) and overall survival (OS). Results: A total of 230 patients with a median age of 68 years (IQR, 62–72 years) were included. All patients underwent curative surgical resection. Of these, 42% received neoadjuvant modified (m) FOLFIRINOX (96/230), 15% received gemcitabine plus nab-paclitaxel (GEM-NAB) (34/230), and 43% received gemcitabine, docetaxel, and capecitabine (GTX) (100/230). In univariate analysis, lower College of American Pathologists (CAP) tumor regression grade (TRG) (0–1 vs. 2–3, median DFS: 29.8 vs. 14.2 months, p = 0.0081) and receipt of ACT (Yes vs. No, median DFS: 22.2 vs. 12.4 months, p < 0.0001) demonstrated significant associations with superior DFS. Multivariable analysis identified receipt of ACT as an independent predictor of superior DFS (HR 0.55, 95% CI: 0.39–0.78, p = 0.0007) and OS (HR 0.49, 95% CI: 0.33–0.71, p = 0.0002). However, the NACT regimen (mFOLFIRINOX vs. GEM-NAB) and the transition between neoadjuvant and adjuvant therapy (de-escalation vs. continuation vs. change) did not correlate with DFS or OS. The duration of perioperative chemotherapy showed a trend toward improved survival outcomes, though not statistically significant (6 months vs. <6 months: DFS, 19.4 vs. 16.2 months, p = 0.1448; OS, 49.6 vs. 30.4 months, p = 0.0623). In the following subgroup analyses, receipt of ACT provided DFS/OS benefits in patients who did not achieve a major pathologic response, pN0, or R0 resection (DFS: p = 0.0003; OS: p < 0.0001). However, it did not provide DFS/OS benefits in those who achieved a major pathologic response with pN0/R0 to NACT (DFS: p = 0.8036; OS: p = 0.1877). Conclusions: In resected pancreatic adenocarcinoma following NACT, receiving ACT was associated with favorable survival outcomes. Additional ACT appears to benefit patients who did not achieve a major pathologic response (pN0 or R0) to neoadjuvant therapy, with limited benefit for those who achieved a major response with pN0/R0. The specific NACT regimen (mFOLFIRINOX vs. GEM-NAB) and changes in ACT from NACT did not significantly influence survival outcomes in our cohort.

9 January 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
Nicole NardellaNicole Nardella
Nicole Nardella
BXBrent Taiting Xia
Brent Taiting Xia
KAKelvin Allenson
Kelvin Allenson
AOAdrianna Oraiqat
Adrianna Oraiqat
WFWenyi Fan
Wenyi Fan
PHPamela Hodul
Pamela Hodul
Background/Objectives: Through survey and analysis of pancreas cancer patient–caregiver dyads, we aimed to identify patient and caregiver characteristics that influence and determine the impact of caregiver coping strategies, self-esteem, and resilience on caregiver distress. Methods: This was a cross-sectional, observational study including pancreatic cancer patients and their caregivers. Demographics of patients and caregivers were collected. Caregivers completed validated instruments (National Comprehensive Cancer Network (NCCN) Distress Thermometer, Caregiver Reaction Assessment (CRA), Perceived Stress Scale 4 (PSS-4), Patient Reported Outcomes Measurement Information System-Anxiety/Depression Short Form (PROMIS-Anxiety/Depression), Brief Resilience Scale (BRS), Zarit Caregiver Burden Interview (CBI-12), and Brief Coping Orientation to Problems Experienced (COPE)) investigating anxiety, depression, perceived stress, caregiver burden, use of approach and avoidant coping, resilience, and self-esteem. Descriptive statistics, univariate, and multiple linear regression models were used to analyze the data. Results: One hundred and fourteen patient–caregiver dyads were included in this study. The majority of patients were male (55%), 65% of caregivers were female, and 64% of patients were receiving palliative intent treatment. Younger caregiver age, more personal care tasks, higher patient distress, and caregiving for a parent were characteristics related to caregiver avoidant coping. Fewer caregiving activities and early clinical stage were associated with caregiver approach coping. High caregivers’ self-esteem was significantly associated with fewer personal care tasks to perform and with caregivers of patients with higher levels of education. Avoidant coping and low resilience were both significantly correlated to distress, anxiety, depression, caregiver burden, and perceived stress. Additionally, low self-esteem was associated with a high perceived caregiver burden. Conclusions: Overall, caregiver factors such as age, relationship with the patient, and number of care tasks and activities influence caregivers coping and self-esteem. Additionally, patient education and clinical stage impacted caregiver coping and self-esteem. Developing interventions to address caregiver coping, self-esteem, and resilience will prove beneficial in improving caregiver distress, anxiety, depression, burden, and perceived stress.

1 June 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
SMSophie Moravec
Sophie Moravec
LBLaura V. Barton
Laura V. Barton
RSRevathy Suresh
Revathy Suresh
LHLaura Hayward
Laura Hayward
TSTara Schmidlen
Tara Schmidlen
JPJennifer Permuth
Jennifer Permuth
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) ranks third in cancer-related deaths. Although national guidelines recommend germline multigene panel testing (MGPT) for all patients with PDAC, only 6%-19% undergo testing, mostly due to under-referral and genetic counselor shortages. We evaluated a coordinator-led and digitally supported workflow designed to increase access to pretest education, improve MGPT uptake, and reduce turnaround time (TAT) for patients newly diagnosed with PDAC at our center. METHODS: Through the Genetic Information for Treatment Decisions (GIFTD) Initiative, a Genetic Risk Education Coordinator (GREC) served as a liaison between providers, genetic counselors, and patients. Subsequently, we partnered with Nest Genomics to develop the GIFTD Partially Automated Nest Copilot (G-PANC), a digital tool that collects cancer history, delivers genetic education, and assesses MGPT interest before coordinator follow-up. Outcomes included genetic education completion, MGPT uptake, and TAT across sequential phases (baseline, GREC-only, and G-PANC [GREC+ Nest Copilot]). RESULTS: Over 1 year, 354 patients with PDAC were invited to access G-PANC; 73% activated accounts, 80% completed education, and 63% expressed MGPT interest. Among those completing education, 86% engaged with the GREC, and 81% consented to testing, including 15 initially uninterested patients. Of the 127 patients tested, 13% had pathogenic variants. Compared with a baseline/traditional workflow, the GREC-only phase was associated with increased MGPT uptake (43% to 80%) and reduced TAT (54 to 30 days). During the subsequent G-PANC phase, testing uptake remained high (77%) and TAT further decreased to 22 days. CONCLUSION: A coordinator-led workflow substantially increased MGPT uptake and reduced TAT. Digital education integration was feasible, maintained high testing rates, and reduced TAT. Prospective evaluation will clarify the independent contributions of digital automation.

28 March 2025 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
ASArpan Sahoo
Arpan Sahoo
GCGabrielle Chin
Gabrielle Chin
LSLaila Stancil
Laila Stancil
AOAdrianna Oraiqat
Adrianna Oraiqat
PHPamela Hodul
Pamela Hodul
Nicole NardellaNicole Nardella
Nicole Nardella
"HSR25-179: Pancreatic Cancer: Expediting Histopathological Diagnosis to Reduce Time to Treatment Initiation" published on 28 Mar 2025 by National Comprehensive Cancer Network.

7 August 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
Nicole NardellaNicole Nardella
Nicole Nardella
MAMatthew Adams
Matthew Adams
AOAdrianna Oraiqat
Adrianna Oraiqat
BGBrian D. Gonzalez
Brian D. Gonzalez
CTCorinne Thomas
Corinne Thomas
SHSarah Hoffe
Sarah Hoffe
Background/Objectives: Pancreatic cancer (PC) is a diagnosis with a poor prognosis which can be associated with significant distress and may hinder a patient’s ability to understand treatment details. Educating patients based on their learning preferences (LPs) and emotions may allow for personalized, enhanced care. Methods: This prospective project enrolled patients with non-metastatic PC. Phase 1 utilized the Learning Preference Barometer (LPB) and Emotional Journey Barometer (EJB), which are digital instruments co-designed by CANCER101 (C101) and the Health Collaboratory, to assess patient LPs and emotional states. Phase 2 provided information prescriptions aligned with LPs through C101’s Prescription to Learn® (P2L) platform. Collected data included demographics, treatment, LPs (auditory, kinesthetic, linguistic, visual), patient engagement with P2L, and patient emotional states with qualitative verbal validation. Descriptive variables were used to report outcomes. Results: Primary LPs in the 47 participating patients were as follows: linguistic 45%, visual 34%, auditory 11%, and kinesthetic 9%, with secondary preferences in the majority (53%). Those patients (66%) who accessed P2L had linguistic and visual preferences; the majority accessed 1- 2 resources out of the 25 provided. Resources accessed aligned to 88% of patient LPs. The majority of patients (60%) initiated treatment prior to initial EJB, and 40% were treatment naive. Common baseline emotions were optimistic (47% vs. 36%, respectively), satisfied (11% vs. 25%), acceptance (11% vs. 11%), and overwhelmed (5% vs. 11%). Conclusions: Assessing LPs and emotional state allows for personalized patient education and clinical encounters for PC patients. Future work includes examining the effects of personalized approaches on patient satisfaction, decision-making, health outcomes, and the overall patient–clinician relationship.

5 April 2024 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
Nicole NardellaNicole Nardella
Nicole Nardella
BGBrian Gonzalez
Brian Gonzalez
MAMatt Adams
Matt Adams
CTCorinne Thomas
Corinne Thomas
AOAdrianna Oraiqat
Adrianna Oraiqat
SHSarah Hoffe
Sarah Hoffe
"HSR24-141: Personalizing the Patient Experience: Understanding the Emotional State and Learning Preferences of Pancreatic Cancer Patients Receiving Multidisciplinary Care" published on 05 Apr 2024 by National Comprehensive Cancer Network.